Drug Profile
Research programme: malaria vaccine - Lipoxen
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Lipoxen Technologies
- Developer National Institutes of Health (USA); Xenetic Biosciences
- Class Antimalarials; Parasitic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Malaria in USA